Last reviewed · How we verify
chemotherapy of mFOLFOX6 or FOLFIRI
mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells.
mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.
At a glance
| Generic name | chemotherapy of mFOLFOX6 or FOLFIRI |
|---|---|
| Also known as | mFOLFOX6 |
| Sponsor | Xu jianmin |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
mFOLFOX6 combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin to inhibit thymidylate synthase and cause DNA crosslinking. FOLFIRI substitutes irinotecan (a topoisomerase I inhibitor) for oxaliplatin. Both regimens work synergistically to prevent cancer cell proliferation and induce apoptosis in colorectal and other solid tumors.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Anemia
- Peripheral neuropathy (oxaliplatin-related)
- Mucositis
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors (PHASE1, PHASE2)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1, PHASE2)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (PHASE1, PHASE2)
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (PHASE1, PHASE2)
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemotherapy of mFOLFOX6 or FOLFIRI CI brief — competitive landscape report
- chemotherapy of mFOLFOX6 or FOLFIRI updates RSS · CI watch RSS
- Xu jianmin portfolio CI